27 Aug Odylia and co-founder Luk Vandenberghe have been named Xconomy Contrarian Awards finalists
Odylia and co-founder Luk Vandenberghe have been named Xconomy Contrarian Awards finalists
After decades of ups and downs, gene therapy’s renaissance is well underway. With one gene therapy, Luxturna, now approved in the U.S., several more are advancing through clinical testing. It’s standard fare now to see pharmaceutical companies buying in to gene therapy programs, or for gene therapy startups to attract venture dollars. What’s far less common is the plan Luk Vandenberghe, the co-director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear, and his colleagues have hatched with Odylia Therapeutics.